Trodelvy (sacituzumab govitecan) Letter of Medical Necessity
Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate targeting Trop-2, delivering SN-38 (active irinotecan metabolite) directly to tumor cells. It holds FDA approvals in pretreated mTNBC, HR+/HER2- metastatic breast cancer, and relapsed urothelial cancer. PA requires precise documentation of prior therapy lines, pathology subtype confirmation, and ECOG status.
FDA-Approved Indications
- ● unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) after ≥2 prior lines of therapy
- ● unresectable locally advanced or metastatic HR+/HER2- breast cancer after endocrine therapy and ≥2 additional lines
- ● locally advanced or metastatic urothelial cancer after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy
Why Trodelvy Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Prior therapy lines not adequately documented (TNBC requires ≥2 prior lines; HR+/HER2- requires endocrine + ≥2 additional lines)
- 2. HER2 status not confirmed as HER2-low or HER2-zero (required to distinguish from Enhertu indication)
- 3. Pathology report not provided confirming TNBC or HR+/HER2- subtype
- 4. ECOG performance status not documented
- 5. UGT1A1 genotyping not addressed (homozygous *28 requires dose reduction)
- 6. Urothelial cancer indication: prior platinum and checkpoint inhibitor therapy not documented
What to Include in a Trodelvy Letter of Medical Necessity
Document tumor histology (pathology confirming TNBC or HR+/HER2- classification, or urothelial carcinoma), prior therapy history with dates, regimens, and progression documentation (at minimum: ≥2 prior systemic lines for TNBC; endocrine therapy + ≥2 additional systemic lines for HR+/HER2-; platinum chemotherapy + PD-1/PD-L1 inhibitor for urothelial), ECOG PS 0-1, metastatic or unresectable disease staging, UGT1A1 genotyping result if available (dose adjustment for *28/*28 homozygotes), and baseline CBC confirming adequate bone marrow reserve.
Key clinical evidence to cite:
- ✓ ASCENT Phase 3 trial — median OS 12.1 vs 6.7 months in pretreated mTNBC (HR 0.48)
- ✓ TROPiCS-02 Phase 3 — OS benefit in HR+/HER2- mBC vs chemotherapy (HR 0.79)
- ✓ TROPHY-U-01 — 27% ORR in platinum/checkpoint inhibitor–relapsed urothelial cancer
- ✓ First Trop-2–targeting ADC approved across breast and urothelial cancers
Relevant guidelines:
- 📖 NCCN Breast Cancer Guidelines (Category 1 for mTNBC)
- 📖 NCCN Bladder Cancer Guidelines
- 📖 ASCO Metastatic Breast Cancer Guidelines
Trodelvy Prior Authorization Criteria
Standard criteria across major US payers for Trodelvy. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior therapy lines not adequately documented (TNBC requires ≥2 prior lines; HR+/HER2- requires endocrine + ≥2 additional lines)
- → Urothelial cancer indication: prior platinum and checkpoint inhibitor therapy not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Trodelvy
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Trodelvy Prior Authorization FAQ
Why was my Trodelvy prior authorization denied?
The most common denial reasons for Trodelvy are: Prior therapy lines not adequately documented (TNBC requires ≥2 prior lines; HR+/HER2- requires endocrine + ≥2 additional lines); HER2 status not confirmed as HER2-low or HER2-zero (required to distinguish from Enhertu indication); Pathology report not provided confirming TNBC or HR+/HER2- subtype; ECOG performance status not documented; UGT1A1 genotyping not addressed (homozygous *28 requires dose reduction); Urothelial cancer indication: prior platinum and checkpoint inhibitor therapy not documented.
What should a Trodelvy Letter of Medical Necessity include?
Document tumor histology (pathology confirming TNBC or HR+/HER2- classification, or urothelial carcinoma), prior therapy history with dates, regimens, and progression documentation (at minimum: ≥2 prior systemic lines for TNBC; endocrine therapy + ≥2 additional systemic lines for HR+/HER2-; platinum chemotherapy + PD-1/PD-L1 inhibitor for urothelial), ECOG PS 0-1, metastatic or unresectable disease staging, UGT1A1 genotyping result if available (dose adjustment for *28/*28 homozygotes), and baseline CBC confirming adequate bone marrow reserve.
Which payers cover Trodelvy?
Trodelvy is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.